miR-16 |
Potential circulating biomarker for bone metastasis |
[3] |
miR-21 |
Functions as an oncogene |
[32] |
|
Highly expressed during osteoclastogenesis |
[24] |
|
Highly detected in osteoclast EVs |
[6] |
miR-31 |
Inhibits breast cancer metastasis |
[33] |
|
Promotes ring-shaped mature osteoclast formation |
[34] |
miR-33a |
Inhibits bone metastasis by targeting PTHrP
|
[31] |
|
Downregulated during osteoclastogenesis |
[3] |
miR-34a |
Inhibits osteoclast differentiation by targeting Tgif2
|
[29] |
|
Attenuates bone metastasis |
[29] |
miR-125a |
Tumor suppressor in breast cancer |
[32] |
|
Upregulated during osteoclastogenesis |
[28] |
|
Inhibits osteoclast differentiation by targeting TRAF6
|
[35] |
miR-133a |
Inhibits osteoclast differentiation by targeting Mitf and Mmp14
|
[3] |
miR-141 |
Inhibits osteoclast differentiation by targeting Mitf and Calcr
|
[3] |
miR-155 |
Highly expressed in invasive tumors |
[32] |
|
Inhibits osteoclastogenesis by repressing MITF and PU.1 |
[25] |
|
Deficiency promotes tumor growth in vivo
|
[36] |
miR-190 |
Inhibits osteoclast differentiation by targeting Calcr
|
[3] |
miR-192 |
Inhibits angiogenesis and decreases bone metastasis |
[37] |
miR-219 |
Inhibits osteoclast differentiation by targeting Mitf and Traf6
|
[3] |
miR-223 |
Inhibits murine osteoclast differentiation |
[21,22] |
|
Decreases breast cancer cell proliferation |
[38] |
miR-326 |
Potential circulating biomarker for bone metastasis |
[39] |
miR-378 |
Potential circulating biomarker for bone metastasis |
[3] |
|
Highly detected in osteoclast EVs |
[6] |
|
Promotes cell survival, tumor growth, and angiogenesis |
[40] |
miR-204/211/379 |
Inhibits TGF-β-induced IL-11 production |
[30] |